Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis B

Authors
Category Primary study
ConferenceHepatology International
Year 2022
This article has no abstract
Epistemonikos ID: 71ea059795ea38e6f03afc308b7578804f8b4843
First added on: Apr 30, 2026